MELK and neoplasm: Moreover, in the TCGA cohort, overexpression of MELK was associated with shorter disease-free survival (DFS) (3.6 years vs. 8.6 years, p < 0.001), more advanced tumor stage and overall stage, lymph node metastasis, and death during follow-up (Fig. 2F-J).